A transgenic, mesodermal specific, Dkk1 mouse model recapitulates a spectrum of human congenital limb reduction defects

Differentiation

Volumn 83, Issue 4, 2012, Pages 220-230

  Dela Cruz, Filemon ^a   Terry, Melissa ^a   Matushansky, Igor ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Dkk1; Limb reduction; Mesenchymal stem cell

Indexed keywords

BETA CATENIN; DICKKOPF 1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DISEASE SEVERITY; FORELIMB; GENOTYPE; HETEROZYGOSITY; HINDLIMB; HOMOZYGOSITY; HUMAN; LIMB REDUCTION DEFECT; MESENCHYMAL STEM CELL; MESODERM; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENE; UPREGULATION;

ANIMALS; BASE SEQUENCE; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DNA PRIMERS; FEMALE; HOMEODOMAIN PROTEINS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIMB DEFORMITIES, CONGENITAL; MALE; MESODERM; MICE; MICE, TRANSGENIC; PEDIGREE;

MUS; MUS MUSCULUS;

EID: 84858782034     PISSN: 03014681     EISSN: 14320436     Source Type: Journal    
DOI: 10.1016/j.diff.2012.01.001     Document Type: Article

References (66)

1. Allard P., Tabin C.J. Achieving bilateral symmetry during vertebrate limb development. Seminars in Cell & Developmental Biology 2009, 20:479-484.
2. Andl T., Reddy S.T., Gaddapara T., Millar S.E. WNT signals are required for the initiation of hair follicle development. Development Cell 2002, 2:643-653.
3. Arango N.A., Szotek P.P., Manganaro T.F., Oliva E., Donahoe P.K., Teixeira J. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Developmental Biology 2005, 288:276-283.
4. Baksh D., Boland G.M., Tuan R.S. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. Journal of Cellular Biochemistry 2007, 101:1109-1124.
5. Baksh D., Tuan R.S. Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. Journal of Cellular Physiology 2007, 212:817-826.
6. Bamias A., Dimopoulos M.A. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opinion on Investigational Drugs 2005, 14:45-55.
7. Barrow J.R., Thomas K.R., Boussadia-Zahui O., Moore R., Kemler R., Capecchi M.R., McMahon A.P. Ectodermal Wnt3/beta-catenin signaling is required for the establishment and maintenance of the apical ectodermal ridge. Genes & Development 2003, 17:394-409.
8. Boland G.M., Perkins G., Hall D.J., Tuan R.S. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. Journal of Cellular Biochemistry 2004, 93:1210-1230.
9. Brembeck F.H., Rosario M., Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Current Opinion in Genetics & Development 2006, 16:51-59.
10. Burtch R.L. Nomenclature for congenital skeletal limb deficiencies, a revision of the Frantz and O'Rahilly classification. Artificial Limbs 1966, 10:24-35.
11. Bwire R., Freeman J., Houn F. Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective. Expert Opinion on Investigational Drugs 2011, 10:3-8.
12. Capdevila J., Izpisua Belmonte J.C. Patterning mechanisms controlling vertebrate limb development. Annual Review of Cell and Develeopment Biology 2001, 17:87-132.
13. Chen M., Doherty S.D., Hsu S. Innovative uses of thalidomide. Dermatology Clinics 2010, 28:577-586.
14. Cobas M., Wilson A., Ernst B., Mancini S.J., MacDonald H.R., Kemler R., Radtke F. Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. Journal of Experimental Medicine 2004, 199:221-229.
15. Cox M.C., Dahut W.L., Figg W.D. The use of thalidomide in androgen-independent prostate cancer. Urologic Oncology 2006, 24:246-249.
16. Cserjesi P., Lilly B., Bryson L., Wang Y., Sassoon D.A., Olson E.N. MHox: a mesodermally restricted homeodomain protein that binds an essential site in the muscle creatine kinase enhancer. Development 1992, 115:1087-1101.
17. Day H.J. The ISO/ISPO classification of congenital limb deficiency. Prosthetics and Orthotics International 1991, 15:67-69.
18. Day T.F., Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Developmental Cell 2005, 8:739-750.
19. Dolk H., Loane M., Garne E. The prevalence of congenital anomalies in Europe. Advances in Experimental Medicine and Biology 2010, 686:349-364.
20. Eleutherakis-Papaiakovou V., Bamias A., Dimopoulos M.A. Thalidomide in cancer medicine. Annals of Oncology 2004, 15:1151-1160.
21. Fleming H.E., Janzen V., Lo Celso C., Guo J., Leahy K.M., Kronenberg H.M., Scadden D.T. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2008, 2:274-283.
22. Foley A., Mercola M. Heart induction: embryology to cardiomyocyte regeneration. Trends in Cardiovascular Medicine 2004, 14:121-125.
23. Franks M.E., Macpherson G.R., Figg W.D. Thalidomide. Lancet 2004, 363:1802-1811.
24. Fulciniti M., Tassone P., Hideshima T., Vallet S., Nanjappa P., Ettenberg S.A., Shen Z., Patel N., Tai Y.T., Chauhan D., Mitsiades C., Prabhala R., Raje N., Anderson K.C., Stover D.R., Munshi N.C. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114:371-379.
25. Furniss D., Kan S.H., Taylor I.B., Johnson D., Critchley P.S., Giele H.P., Wilkie A.O. Genetic screening of 202 individuals with congenital limb malformations and requiring reconstructive surgery. Journal of Medical Genetics 2009, 46:730-735.
26. Galloway J.L., Delgado I., Ros M.A., Tabin C.J. A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature 2009, 460:400-404.
27. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., Taketo M.M., Long F., McMahon A.P., Lang R.A., Karsenty G. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Developmental Cell 2005, 8:751-764.
28. Glinka A., Wu W., Delius H., Monaghan A.P., Blumenstock C., Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362.
29. Gregory C.A., Singh H., Perry A.S., Prockop D.J. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. Journal of Biological Chemistry 2003, 278:28067-28078.
30. Hall C.B., Brooks M.B., Dennis J.F. Congenital skeletal deficiencies of the extremities. Classification and fundamentals of treatment. Journal of the American Medical Association 1962, 181:590-599.
31. Hill T.P., Spater D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Developmental Cell 2005, 8:727-738.
32. Hill T.P., Taketo M.M., Birchmeier W., Hartmann C. Multiple roles of mesenchymal beta-catenin during murine limb patterning. Development 2006, 133:1219-1229.
33. Knobloch J., Schmitz I., Gotz K., Schulze-Osthoff K., Ruther U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Molecular Cell Biology 2008, 28:529-538.
34. Knobloch J., Shaughnessy J.D., Ruther U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB Journal 2007, 21:1410-1421.
35. Ko J.Y., Wang F.S., Wang C.J., Wong T., Chou W.Y., Tseng S.L. Increased Dickkopf-1 expression accelerates bone cell apoptosis in femoral head osteonecrosis. Bone 2010, 46:584-591.
36. Komatsu D.E., Mary M.N., Schroeder R.J., Robling A.G., Turner C.H., Warden S.J. Modulation of Wnt signaling influences fracture repair. Journal of Orthopaedic Research 2010, 28:928-936.
37. Ladizinski B., Shannon E.J., Sanchez M.R., Levis W.R. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. Journal of Drugs in Dermatology 2010, 9:814-826.
38. Lee A.Y., He B., You L., Xu Z., Mazieres J., Reguart N., Mikami I., Batra S., Jablons D.M. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochemical and Biophysical Research Communications 2004, 323:1246-1250.
39. Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., Morony S., Adamu S., Geng Z., Qiu W., Kostenuik P., Lacey D.L., Simonet W.S., Bolon B., Qian X., Shalhoub V., Ominsky M.S., Zhu-Ke H., Li X., Richards W.G. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006, 39:754-766.
40. Li X., Grisanti M., Fan W., Asuncion F.J., Tan H.L., Dwyer D., Han C.Y., Yu L., Lee J., Lee E., Barrero M., Kurimoto P., Niu Q.T., Geng Z., Winters A., Horan T., Steavenson S., Jacobsen F., Chen Q., Haldankar R., Lavallee J., Tipton B., Daris M., Sheng J., Lu H.S., Daris K., Deshpande R., Valente E.G., Salimi-Moosavi H., Kostenuik P.J., Li J., Liu M., Li C., Lacey D.L., Simonet W.S., Ke H.Z., Babij P., Stolina M., Ominsky M.S., Richards W.G. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. Journal of Bone and Mineral Research 2011, 26:2610-2621.
41. Logan M., Martin J.F., Nagy A., Lobe C., Olson E.N., Tabin C.J. Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis 2002, 33:77-80.
42. Mariani F.V., Martin G.R. Deciphering skeletal patterning: clues from the limb. Nature 2003, 423:319-325.
43. Martin J.F., Olson E.N. Identification of a prx1 limb enhancer. Genesis 2000, 26:225-229.
44. Matushansky I., Hernando E., Socci N.D., Mills J.E., Matos T.A., Edgar M.A., Singer S., Maki R.G., Cordon-Cardo C. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. Journal of Clinical Investigation 2007, 117:3248-3257.
45. Matushansky I., Maki R.G., Cordon-Cardo C. A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell Cycle 2008, 7:720-724.
46. Mikheev A.M., Mikheeva S.A., Liu B., Cohen P., Zarbl H. A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. Carcinogenesis 2004, 25:47-59.
47. Mills J., Hricik T., Siddiqi S., Matushansky I. Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. Molecular Cancer Therapeutics 2011, 10:313-324.
48. Paravar T., Lee D.J. Thalidomide: mechanisms of action. International Reviews of Immunology 2008, 27:111-135.
49. Saitou M., Sugai S., Tanaka T., Shimouchi K., Fuchs E., Narumiya S., Kakizuka A. Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor. Nature 1995, 374:159-162.
50. Schambony A., Kunz M., Gradl D. Cross-regulation of Wnt signaling and cell adhesion. Differentiation; Research in Biological Diversity 2004, 72:307-318.
51. Sinn E., Muller W., Pattengale P., Tepler I., Wallace R., Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987, 49:465-475.
52. Song L.N., Gelmann E.P. Silencing mediator for retinoid and thyroid hormone receptor and nuclear receptor corepressor attenuate transcriptional activation by the beta-catenin-TCF4 complex. Journal of Biological Chemistry 2008, 283:25988-25999.
53. Soshnikova N., Zechner D., Huelsken J., Mishina Y., Behringer R.R., Taketo M.M., Crenshaw E.B., Birchmeier W. Genetic interaction between Wnt/beta-catenin and BMP receptor signaling during formation of the AER and the dorsal-ventral axis in the limb. Genes & Development 2003, 17:1963-1968.
54. Stewart T.A., Pattengale P.K., Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38:627-637.
55. Sun X., Mariani F.V., Martin G.R. Functions of FGF signalling from the apical ectodermal ridge in limb development. Nature 2002, 418:501-508.
56. Tabin C., Wolpert L. Rethinking the proximodistal axis of the vertebrate limb in the molecular era. Genes & Development 2007, 21:1433-1442.
57. Teo S.K., Resztak K.E., Scheffler M.A., Kook K.A., Zeldis J.B., Stirling D.I., Thomas S.D. Thalidomide in the treatment of leprosy. Microbes and Infection 2002, 4:1193-1202.
58. Teo S.K., Stirling D.I., Zeldis J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discovery Today 2005, 10:107-114.
59. Therapontos C., Erskine L., Gardner E.R., Figg W.D., Vargesson N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proceedings of the National Academy Sciences USA 2009, 106:8573-8578.
60. Tremblay P.J., Pothier F., Hoang T., Tremblay G., Brownstein S., Liszauer A., Jolicoeur P. Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues. Molecular Cell Biology 1989, 9:854-859.
61. Vargesson N. Thalidomide-induced limb defects: resolving a 50-year-old puzzle. Bioessays 2009, 31:1327-1336.
62. Vijayakumar S., Liu G., Rus I.A., Yao S., Chen Y., Akiri G., Grumolato L., Aaronson S.A. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/beta-catenin target gene, CDC25A. Cancer Cell 2011, 19:601-612.
63. Wang F.S., Ko J.Y., Yeh D.W., Ke H.C., Wu H.L. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 2008, 149:1793-1801.
64. Weng L.H., Wang C.J., Ko J.Y., Sun Y.C., Su Y.S., Wang F.S. Inflammation induction of Dickkopf-1 mediates chondrocyte apoptosis in osteoarthritic joint. Osteoarthritis Cartilage 2009, 17:933-943.
65. Wolpert L., Tickle C., Sampford M. The effect of cell killing by x-irradiation on pattern formation in the chick limb. Journal of Embryology & Experimental Morphology 1979, 50:175-193.
66. Yokoyama H., Maruoka T., Ochi H., Aruga A., Ohgo S., Ogino H., Tamura K. Different requirement for Wnt/beta-catenin signaling in limb regeneration of larval and adult Xenopus. PLoS One 2011, 6:e21721.